Colistin monotherapy vs. combination therapy: Evidence from microbiological, animal and clinical studies

N. Petrosillo, E. Ioannidou, M. E. Falagas

Research output: Contribution to journalArticle

Abstract

Colistin is commonly the last resort for treatment of infections caused by multidrug-resistant Gram-negative bacteria. In clinical practice, it is frequently used as combination therapy in order to improve its antibacterial activity, despite the consequent increase in toxicity. The available evidence from various studies (microbiological, animal and clinical studies, retrieved from the PubMed and Scopus databases) regarding the comparative effectiveness of colistin monotherapy and colistin combination therapy was evaluated. Most of the microbiological studies examined colistin monotherapy vs. combinations with rifampicin (nine studies) or carbapenems (three studies) for Pseudomonas aeruginosa or Acinetobacter baumannii infections. A synergistic effect was detected in all the studies examining the combination of colistin and rifampicin, whereas carbapenems exhibited a synergistic effect in two of three studies. Most of the animal studies examined colistin monotherapy vs. combinations with rifampicin, carbenicillin, piperacillin and imipenem for treatment of P..aeruginosa, A..baumannii or Escherichia coli infections. Mortality rates were significantly lower in the combination treatment arm in three of six relevant studies. However, data from the small number (four) of relevant human studies suggest non-inferiority of colistin monotherapy as compared with combination therapy. In conclusion, microbiological studies suggest superiority of colistin combination treatment, which is in contrast to preliminary data from studies in humans. Results from animal study data are equivocal. There is an urgent need for appropriately designed and powered clinical trials addressing this apparently controversial situation.

Original languageEnglish
Pages (from-to)816-827
Number of pages12
JournalClinical Microbiology and Infection
Volume14
Issue number9
DOIs
Publication statusPublished - 2008

Fingerprint

Colistin
Rifampin
Carbapenems
Therapeutics
Acinetobacter Infections
Carbenicillin
Escherichia coli Infections
Acinetobacter baumannii
Piperacillin
Clinical Studies
Imipenem
Gram-Negative Bacteria
PubMed
Pseudomonas aeruginosa
Clinical Trials
Databases
Mortality

Keywords

  • Acinetobacter baumannii
  • Bacteraemia
  • Carbapenem
  • Escherichia coli
  • Klebsiella pneumoniae
  • Multiple drug resistance
  • Pneumonia
  • Polymyxins
  • Pseudomonas aeruginosa
  • Rifampicin

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

Cite this

Colistin monotherapy vs. combination therapy : Evidence from microbiological, animal and clinical studies. / Petrosillo, N.; Ioannidou, E.; Falagas, M. E.

In: Clinical Microbiology and Infection, Vol. 14, No. 9, 2008, p. 816-827.

Research output: Contribution to journalArticle

@article{c7a0848627ee429e85e7f871dacd4ae1,
title = "Colistin monotherapy vs. combination therapy: Evidence from microbiological, animal and clinical studies",
abstract = "Colistin is commonly the last resort for treatment of infections caused by multidrug-resistant Gram-negative bacteria. In clinical practice, it is frequently used as combination therapy in order to improve its antibacterial activity, despite the consequent increase in toxicity. The available evidence from various studies (microbiological, animal and clinical studies, retrieved from the PubMed and Scopus databases) regarding the comparative effectiveness of colistin monotherapy and colistin combination therapy was evaluated. Most of the microbiological studies examined colistin monotherapy vs. combinations with rifampicin (nine studies) or carbapenems (three studies) for Pseudomonas aeruginosa or Acinetobacter baumannii infections. A synergistic effect was detected in all the studies examining the combination of colistin and rifampicin, whereas carbapenems exhibited a synergistic effect in two of three studies. Most of the animal studies examined colistin monotherapy vs. combinations with rifampicin, carbenicillin, piperacillin and imipenem for treatment of P..aeruginosa, A..baumannii or Escherichia coli infections. Mortality rates were significantly lower in the combination treatment arm in three of six relevant studies. However, data from the small number (four) of relevant human studies suggest non-inferiority of colistin monotherapy as compared with combination therapy. In conclusion, microbiological studies suggest superiority of colistin combination treatment, which is in contrast to preliminary data from studies in humans. Results from animal study data are equivocal. There is an urgent need for appropriately designed and powered clinical trials addressing this apparently controversial situation.",
keywords = "Acinetobacter baumannii, Bacteraemia, Carbapenem, Escherichia coli, Klebsiella pneumoniae, Multiple drug resistance, Pneumonia, Polymyxins, Pseudomonas aeruginosa, Rifampicin",
author = "N. Petrosillo and E. Ioannidou and Falagas, {M. E.}",
year = "2008",
doi = "10.1111/j.1469-0691.2008.02061.x",
language = "English",
volume = "14",
pages = "816--827",
journal = "Clinical Microbiology and Infection",
issn = "1198-743X",
publisher = "Elsevier B.V.",
number = "9",

}

TY - JOUR

T1 - Colistin monotherapy vs. combination therapy

T2 - Evidence from microbiological, animal and clinical studies

AU - Petrosillo, N.

AU - Ioannidou, E.

AU - Falagas, M. E.

PY - 2008

Y1 - 2008

N2 - Colistin is commonly the last resort for treatment of infections caused by multidrug-resistant Gram-negative bacteria. In clinical practice, it is frequently used as combination therapy in order to improve its antibacterial activity, despite the consequent increase in toxicity. The available evidence from various studies (microbiological, animal and clinical studies, retrieved from the PubMed and Scopus databases) regarding the comparative effectiveness of colistin monotherapy and colistin combination therapy was evaluated. Most of the microbiological studies examined colistin monotherapy vs. combinations with rifampicin (nine studies) or carbapenems (three studies) for Pseudomonas aeruginosa or Acinetobacter baumannii infections. A synergistic effect was detected in all the studies examining the combination of colistin and rifampicin, whereas carbapenems exhibited a synergistic effect in two of three studies. Most of the animal studies examined colistin monotherapy vs. combinations with rifampicin, carbenicillin, piperacillin and imipenem for treatment of P..aeruginosa, A..baumannii or Escherichia coli infections. Mortality rates were significantly lower in the combination treatment arm in three of six relevant studies. However, data from the small number (four) of relevant human studies suggest non-inferiority of colistin monotherapy as compared with combination therapy. In conclusion, microbiological studies suggest superiority of colistin combination treatment, which is in contrast to preliminary data from studies in humans. Results from animal study data are equivocal. There is an urgent need for appropriately designed and powered clinical trials addressing this apparently controversial situation.

AB - Colistin is commonly the last resort for treatment of infections caused by multidrug-resistant Gram-negative bacteria. In clinical practice, it is frequently used as combination therapy in order to improve its antibacterial activity, despite the consequent increase in toxicity. The available evidence from various studies (microbiological, animal and clinical studies, retrieved from the PubMed and Scopus databases) regarding the comparative effectiveness of colistin monotherapy and colistin combination therapy was evaluated. Most of the microbiological studies examined colistin monotherapy vs. combinations with rifampicin (nine studies) or carbapenems (three studies) for Pseudomonas aeruginosa or Acinetobacter baumannii infections. A synergistic effect was detected in all the studies examining the combination of colistin and rifampicin, whereas carbapenems exhibited a synergistic effect in two of three studies. Most of the animal studies examined colistin monotherapy vs. combinations with rifampicin, carbenicillin, piperacillin and imipenem for treatment of P..aeruginosa, A..baumannii or Escherichia coli infections. Mortality rates were significantly lower in the combination treatment arm in three of six relevant studies. However, data from the small number (four) of relevant human studies suggest non-inferiority of colistin monotherapy as compared with combination therapy. In conclusion, microbiological studies suggest superiority of colistin combination treatment, which is in contrast to preliminary data from studies in humans. Results from animal study data are equivocal. There is an urgent need for appropriately designed and powered clinical trials addressing this apparently controversial situation.

KW - Acinetobacter baumannii

KW - Bacteraemia

KW - Carbapenem

KW - Escherichia coli

KW - Klebsiella pneumoniae

KW - Multiple drug resistance

KW - Pneumonia

KW - Polymyxins

KW - Pseudomonas aeruginosa

KW - Rifampicin

UR - http://www.scopus.com/inward/record.url?scp=50149096410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50149096410&partnerID=8YFLogxK

U2 - 10.1111/j.1469-0691.2008.02061.x

DO - 10.1111/j.1469-0691.2008.02061.x

M3 - Article

C2 - 18844682

AN - SCOPUS:50149096410

VL - 14

SP - 816

EP - 827

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

SN - 1198-743X

IS - 9

ER -